Literature DB >> 12593899

Interleukin-1beta gene polymorphism in women with vulvar vestibulitis syndrome.

Stefan Gerber1, Ann Marie Bongiovanni, William J Ledger, Steven S Witkin.   

Abstract

OBJECTIVE: The pathogenesis of vulvar vestibulitis syndrome remains unknown but may be related to a localized chronic inflammation. The relation between this syndrome and a polymorphism at position +3953 in the interleukin-1beta gene was examined. Allele 2 of this gene has been associated with increased pro-inflammatory immunity. STUDY
DESIGN: Buccal or vestibular swabs from 59 women with strictly defined vulvar vestibulitis and from 48 healthy women were tested by polymerase chain reaction for the presence of two alleles at the +3953 interleukin-1beta locus.
RESULTS: Allele 2 of the interleukin-1beta gene was identified in 27 (46%) women with vulvar vestibulitis as opposed to 12 (25%) control women (P=0.03). The interleukin-1beta 1,1 genotype was present in 36 (75%) controls as opposed to 32 (54%) vulvar vestibulitis syndrome patients (P=0.02). All subjects had been previously tested for induced interleukin-1beta production in response to bacterial lipopolysaccharide. In both patients and controls, possession of allele 2 was associated with a small but non-statistically significant increase in induced interleukin-1beta production.
CONCLUSION: Allele 2 in the interleukin-1beta gene is more common in women with vulvar vestibulitis syndrome than in other women. Susceptibility to vulvar vestibulitis syndrome might be influenced by carriage of this polymorphism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12593899     DOI: 10.1016/s0301-2115(02)00276-2

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  13 in total

1.  The vaginal microbiome in health and disease.

Authors:  Bryan A White; Douglas J Creedon; Karen E Nelson; Brenda A Wilson
Journal:  Trends Endocrinol Metab       Date:  2011-07-13       Impact factor: 12.015

Review 2.  Treatment of Vulvodynia: Pharmacological and Non-Pharmacological Approaches.

Authors:  Natalie O Rosen; Samantha J Dawson; Melissa Brooks; Susan Kellogg-Spadt
Journal:  Drugs       Date:  2019-04       Impact factor: 9.546

3.  Peripheral interleukin-1ß levels are elevated in chronic tension-type headache patients.

Authors:  Chris Della Vedova; Stuart Cathcart; Alan Dohnalek; Vanessa Lee; Mark R Hutchinson; Maarten A Immink; John Hayball
Journal:  Pain Res Manag       Date:  2013-08-16       Impact factor: 3.037

4.  The bacterial microbiome in paired vaginal and vestibular samples from women with vulvar vestibulitis syndrome.

Authors:  Aswathi Jayaram; Steven S Witkin; Xia Zhou; Celeste J Brown; Gustavo E Rey; Iara M Linhares; William J Ledger; Larry J Forney
Journal:  Pathog Dis       Date:  2014-07-10       Impact factor: 3.166

5.  Allergic reactions and risk of vulvodynia.

Authors:  Bernard L Harlow; Wei He; Ruby H N Nguyen
Journal:  Ann Epidemiol       Date:  2009-11       Impact factor: 3.797

Review 6.  Progress in genetic studies of pain and analgesia.

Authors:  Michael L Lacroix-Fralish; Jeffrey S Mogil
Journal:  Annu Rev Pharmacol Toxicol       Date:  2009       Impact factor: 13.820

Review 7.  Vulvodynia.

Authors:  Sophie Bergeron; Barbara D Reed; Ursula Wesselmann; Nina Bohm-Starke
Journal:  Nat Rev Dis Primers       Date:  2020-04-30       Impact factor: 52.329

8.  GCH1-polymorphism and pain sensitivity among women with provoked vestibulodynia.

Authors:  Ulrika Heddini; Nina Bohm-Starke; Alfhild Grönbladh; Fred Nyberg; Kent W Nilsson; Ulrika Johannesson
Journal:  Mol Pain       Date:  2012-09-12       Impact factor: 3.395

9.  Vulvar vestibulitis syndrome.

Authors:  Carolyn Gardella
Journal:  Curr Infect Dis Rep       Date:  2006-11       Impact factor: 3.663

10.  A genome-wide association study of female sexual dysfunction.

Authors:  Andrea Burri; Pirro Hysi; Alex Clop; Qazi Rahman; Tim D Spector
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.